Antiplatelet resistance in stroke

Expert Review of Neurotherapeutics

Volumn 11, Issue 2, 2011, Pages 251-263

  Topçuoglu, Mehmet Akif ^a   Arsava, Ethem Murat ^a   Ay, Hakan ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alopidogrel; Antiplatelet; Aspirin; Ischemic stroke; Non response; Platelet function assay; Point of care; Resistance; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIHYDROPYRIDINE; DIPYRIDAMOLE; ELINOGREL; GLUCURONOSYLTRANSFERASE 1A6; GLYCOPROTEIN P; IBUPROFEN; INDOMETACIN; MEVINOLIN; MULTIDRUG RESISTANCE PROTEIN 1; NAPROXEN; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; SIMVASTATIN; THROMBOXANE A2; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BRAIN ISCHEMIA; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TREATMENT FAILURE; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; LABORATORY TEST; LOADING DRUG DOSE; PATIENT COMPLIANCE; POINT OF CARE TESTING; RECURRENT DISEASE; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK;

ACUTE CORONARY SYNDROME; ASPIRIN; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECURRENCE; RISK; STROKE; TICLOPIDINE;

EID: 79951665150     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.203     Document Type: Review

References (124)

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121(7), e46-e215 (2010).
2. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 367(9510), 606-617 (2006). (Pubitemid 43250663)
3. Breet NJ, van Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8), 754-762 (2010).
4. Michelson AD. Methods for the measurement of platelet function. Am. J. Cardiol. 103(3 Suppl.), A20-A26 (2009).
5. Jeon SB, Song HS, Kim BJ et al. Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur. Neurol. 64(1), 51-57 (2010).
6. Cuisset T, Frere C, Quilici J, Uhry S, Alessi MC, Bonnet JL. Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment? Int. J. Cardiol. 138(2), 212-213 (2010).
7. May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting. A double-edged sword between thrombosis and bleeding. Thromb. Haemost. 99(3), 487-493 (2008). (Pubitemid 351559482)
8. Collet JP, Montalescot G. Platelet function testing and implications for clinical practice. J. Cardiovasc. Pharmacol. Ther. 14(3), 157-169 (2009).
9. Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb. Haemost. 102(2), 404-411 (2009).
10. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart. J. 28(14), 1702-1708 (2007). (Pubitemid 47227104)
11. Santilli F, Rocca B, De Cristofaro R et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin resistance . J. Am. Coll. Cardiol. 53(8), 667-677 (2009).
12. Cuisset T, Frere C, Poyet R et al. Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. Arch. Cardiovasc. Dis. 103(1), 39-45 (2010).
13. Gurbel PA, Bliden KP, DiChiara J et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 115(25), 3156-3164 (2007). (Pubitemid 47012230)
14. Broadley AJ, Gapper P, Schmitt M, Frenneaux MP. Supine rest reduces platelet activation and aggregation. Platelets 14(1), 3-7 (2003). (Pubitemid 36237733)
15. Smock KJ, Rodgers GM. Laboratory evaluation of aspirin responsiveness. Am. J. Hematol. 85(5), 358-360 (2010).
16. Grotemeyer KH. The platelet-reactivity-test - a useful by-product of the blood-sampling procedure? Thromb. Res. 61(4), 423-431 (1991).
17. Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets 11(6), 320-324 (2000).
18. Pamukcu B, Oflaz H, Acar RD et al. The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation. J. Thromb. Thrombolysis 20(1), 17-22 (2005). (Pubitemid 41300616)
19. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. Thromb. Res. 124(5), 588-591 (2009).
20. Addad F, Chakroune T, Asma A et al. Clopidogrel but not Aspirin prevents acute smoking-induced platelet aggregation in patients with stable coronary artery disease. Thromb. Res. 123(4), 640-643 (2009).
21. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J. Thromb. Haemost. 8(1), 37-42 (2010).
22. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin. Thromb. Hemost. 35(3), 295-306 (2009).
23. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J. Thromb. Haemost. 5(3), 507-511 (2007). (Pubitemid 46680683)
24. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int. J. Obes. Relat. Metab. Disord. 27(8), 907-911 (2003). (Pubitemid 36918612)
25. Ertugrul DT, Tutal E, Yildiz M et al. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95(6), 2897-2901 (2010).
26. Hovens MM, Snoep JD, Groeneveld Y, Tamsma JT, Eikenboom JC, Huisman MV. High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. J. Thromb. Haemost. 5(7), 1562-1564 (2007). (Pubitemid 46965391)
27. Lee PY, Chen WH, Ng W et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am. J. Med. 118(7), 723-727 (2005). (Pubitemid 40897657)
28. Karepov V, Tolpina G, Kuliczkowski W, Serebruany V. Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. Cerebrovasc. Dis. 26(3), 272-276 (2008).
29. Bouman HJ, van Werkum JW, Hackeng CM, Verheugt FW, Ten Berg JM. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J. Thromb. Haemost. 6(6), 1040-1042 (2008). (Pubitemid 351689930)
30. Mansour K, Taher AT, Musallam KM, Alam S. Aspirin resistance. Adv. Hematol. 2009, 937352 (2009).
31. Hedegaard SS, Hvas AM, Grove EL et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb. Res. 124(1), 96-100 (2009).
32. Alberts MJ. Platelet function testing for aspirin resistance is reasonable to do: yes! Stroke 41(10), 2400-2401 (2010).
33. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13(8), 493-497 (2002). (Pubitemid 35373664)
34. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J. Neurol. 50(1), 63-66 (2003). (Pubitemid 36206686)
35. Linnemann B, Schwonberg J, Toennes SW, Mani H, Lindhoff-Last E. Variability of residual platelet function despite clopidogrel treatment in patients with peripheral arterial occlusive disease. Atherosclerosis 209(2), 504-509 (2010).
36. Lev EI. Aspirin resistance transient laboratory finding or important clinical entity? J. Coll. Cardiol. 53(8), 678-680 (2009).
37. Helgason CM, Bolin KM, Hoff JA et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25(12), 2331-2336 (1994). (Pubitemid 24359298)
38. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J. Transl. Med. 6, 46 (2008).
39. Serebruany V, Cherala G, Williams C et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of resistance Am. Heart J. 158(6), 925-932 (2009).
40. Hamann GF, Weimar C, Glahn J, Busse O, Diener HC. Adherence to secondary stroke prevention strategies - results from the German Stroke Data Bank. Cerebrovasc. Dis. 15(4), 282-288 (2003). (Pubitemid 36438733)
41. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am. J. Cardiovasc. Drugs 10(2), 125-141 (2010).
42. Cuisset T, Frere C, Quilici J et al. Aspirin noncompliance is the major cause of aspirin resistance in patients undergoing coronary stenting. Am. Heart J. 157(5), 889-893 (2009).
43. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 37(8), 2153-2158 (2006). (Pubitemid 44309919)
44. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115(16), 2196-2207 (2007). (Pubitemid 46659072)
45. Schwertner HA, McGlasson D, Christopher M, Bush AC. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb. Res. 118(4), 529-534 (2006). (Pubitemid 44404044)
46. Catella-Lawson F, Reilly MP, Kapoor SC et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345(25), 1809-1817 (2001).
47. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51(3), 256-260 (2008).
48. Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors and Clopidogrel Association) prospective randomized study. J. Am. Coll. Cardiol. 54(13), 1149-1153 (2009).
49. Small DS, Farid NA, Payne CD et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J. Clin. Pharmacol. 48(4), 475-484 (2008). (Pubitemid 351389118)
50. Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101(4), 714-719 (2009).
51. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7), 713-718 (2009).
52. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9), 937-944 (2009).
53. O Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694), 989-997 (2009).
54. Rassen JA, Choudhry NK, Avorn J, Schneeweiss S. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120(23), 2322-2329 (2009).
55. Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107(1), 32-37 (2003). (Pubitemid 36070929)
56. Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur. Heart J. 24(19), 1744-1749 (2003). (Pubitemid 37236863)
57. Saw J, Steinhubl SR, Berger PB et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108(8), 921-924 (2003). (Pubitemid 37048218)
58. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 109(11), 1335-1338 (2004). (Pubitemid 38387816)
59. Saw J, Brennan DM, Steinhubl SR et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J. Am. Coll. Cardiol. 50(4), 291-295 (2007). (Pubitemid 47058889)
60. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart 96(3), 186-189 (2010).
61. Harmsze AM, Robijns K, van Werkum JW et al. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb. Haemost. 103(5), 920-925 (2010).
62. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J. Am. Coll. Cardiol. 52(19), 1557-1563 (2008).
63. Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin. Genet. 75(1), 1-18 (2009).
64. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br. J. Clin. Pharmacol. 66(2), 222-232 (2008).
65. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009).
66. Sugunaraj JP, Palaniswamy C, Selvaraj DR, Chaitanya Arudra SK, Sukhija R. Clopidogrel resistance. Am. J. Ther. 17(2), 210-215 (2010).
67. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660), 309-317 (2009).
68. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 111(16), 2099-2106 (2005). (Pubitemid 40577905)
69. Seip RL, Duconge J, Ruano G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 6(3), 409-424 (2010).
70. Michelson AD, Cattaneo M, Eikelboom JW et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 3(6), 1309-1311 (2005). (Pubitemid 41725257)
71. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J. Am. Coll. Cardiol. 51(19), 1829-1843 (2008). (Pubitemid 351615246)
72. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract. Res. Clin. Endocrinol. Metab. 23(3), 375-388 (2009).
73. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb. Haemost. 101(1), 151-156 (2009).
74. Gaborit B, Frere C, Cuisset T, Alessi MC, Dutour A. Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control. J. Thromb. Haemost. 7(11), 1939-1941 (2009).
75. Pamukcu B, Oflaz H, Onur I et al. Relationship between the serum sCD40L level and aspirin-resistant platelet aggregation in patients with stable coronary artery disease. Circ. J. 72(1), 61-66 (2008). (Pubitemid 351413328)
76. Erlinge D, Varenhorst C, Braun OO et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll. Cardiol. 52(24), 1968-1977 (2008).
77. Simon DI, Schmaier AH. Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J. Am. Coll. Cardiol. 50(16), 1548-1550 (2007).
78. Watala C, Pluta J, Golanski J et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med. 83(2), 148-158 (2005). (Pubitemid 40379303)
79. Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am. J. Cardiol. 98(10A), 4N-10N (2006).
80. Ohmori T, Yatomi Y, Nonaka T et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J. Thromb. Haemost. 4(6), 1271-1278 (2006).
81. Harrison P KD. Laboratory monitoring of antiplatelet therapy. In:Platelets in Hematologic and Cardiovascular Disorders - A Clinical Handbook. Gresele P, Fuster V, Lopez J, Page C, Vermylen J (Eds). Cambridge University Press, Cambridge, UK, 386-407 (2008).
82. Favaloro EJ. Clinical utility of the PFA-100. Semin. Thromb. Hemost. 34(8), 709-733 (2008).
83. Harrison P KD. Clinical tests of platelet function. In:Platelets. Michelson A (Ed.). Elsevier Inc./Academic Press, CA, USA, 445-474 (2007).
84. Velik-Salchner C, Maier S, Innerhofer P et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth. Analg. 107(6), 1798-1806 (2008).
85. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71(5), 397-403 (1993).
86. Gengo FM, Rainka M, Robson M et al. Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J. Clin. Pharmacol. 48(3), 335-343 (2008). (Pubitemid 351257777)
87. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167(15), 1593-1599 (2007). (Pubitemid 47280339)
88. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin resistance and risk of cardiovascular morbidity: stematic review and meta-analysis. BMJ 336(7637), 195-198 (2008). (Pubitemid 351212675)
89. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154(2), 221-231 (2007). (Pubitemid 47069129)
90. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51(14), 1404-1411 (2008). (Pubitemid 351447314)
91. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am. Heart J. 153(2), 175-181 (2007). (Pubitemid 46096871)
92. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71-86 (2002).
93. Gladding P, Webster M, Zeng I et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv. 1(6), 620-627 (2008).
94. Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol. 47(1), 27-33 (2006). (Pubitemid 43005160)
95. Milicic D, Skoric B, Lovric D. Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis. J. Invasive Cardiol. 21(8), E157-E160 (2009).
96. Campo G, Valgimigli M, Gemmati D et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism? Evidence from a clopidogrel-to-ticlopidine crossover study. J. Am. Coll. Cardiol. 50(12), 1132-1137 (2007). (Pubitemid 47375009)
97. Gladding P, Webster M, Ormiston J, Olsen S, White H. Antiplatelet drug nonresponsiveness. Am. Heart J. 155(4), 591-599 (2008). (Pubitemid 351400760)
98. Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am. J. Cardiol. 101(7), 1060-1063 (2008).
99. Schroeder WS, Ghobrial L, Gandhi PJ. Possible mechanisms of drug-induced aspirin and clopidogrel resistance. J. Thromb. Thrombolysis 22(2), 139-150 (2006). (Pubitemid 44473565)
100. Neubauer H, Engelhardt A, Kruger JC et al. Pantoprazole does not influence the antiplatelet effect of clopidogrel - a whole blood aggregometry study following coronary stenting. J. Cardiovasc. Pharmacol. 56(1), 91-97 (2010).
101. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch. Intern. Med. 170(8), 704-710 (2010).
102. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Circulation 122(24), 2619-2633 (2010).
103. Bhindi R, Ormerod O, Newton J, Banning AP, Testa L. Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 101(12), 915-925 (2008).
104. Berger PB, Bhatt DL, Fuster V et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121(23), 2575-2583 (2010).
105. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res. 63(6), 587-593 (1991).
106. Helgason CM, Tortorice KL, Winkler SR et al. Aspirin response and failure in cerebral infarction. Stroke 24(3), 345-350 (1993). (Pubitemid 23070037)
107. Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A. Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 34(4), 849-854 (2003). (Pubitemid 36402949)
108. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35(1), 175-178 (2004). (Pubitemid 38057615)
109. Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J. Thromb. Haemost. 2(11), 2051-2053 (2004). (Pubitemid 40192762)
110. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36(5), 1001-1005 (2005). (Pubitemid 40629292)
111. McCabe DJ, Harrison P, Mackie IJ et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16(5), 269-280 (2005). (Pubitemid 40943921)
112. Berrouschot J, Schwetlick B, von Twickel G et al. Aspirin resistance in secondary stroke prevention. Acta Neurol. Scand. 113(1), 31-35 (2006).
113. Hohlfeld T, Weber AA, Junghans U et al. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc. Dis. 24(1), 43-50 (2007). (Pubitemid 47026140)
114. Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM. A pilot study of resistance to aspirin in stroke patients. J. Clin. Neurosci. 15(11), 1204-1209 (2008).
115. Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J. Cereb. Blood Flow Metab. 28(6), 1196-1203 (2008). (Pubitemid 351733359)
116. Seok JI, Joo IS, Yoon JH et al. Can aspirin resistance be clinically predicted in stroke patients? Clin. Neurol. Neurosurg. 110(2), 110-116 (2008).
117. Cha JK, Jeon HW, Kang MJ. ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. Eur. J. Neurol. 15(12), 1304-1308 (2008).
118. Boncoraglio GB, Bodini A, Brambilla C, Corsini E, Carriero MR, Parati EA. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin. Neurol. Neurosurg. 111(3), 270-273 (2009).
119. Bernstein PL, Jacobson BF, Connor MD, Becker PJ. Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. J. Neurol. Sci. 277(1-2), 80-82 (2009).
120. von Lewinski F, Riggert J, Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis? J. Stroke Cerebrovasc. Dis. 18(2), 111-115 (2009).
121. Lee JH, Cha JK, Lee SJ, Ha SW, Kwon SU. Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. Eur. J. Neurol. 17(3), 434-442 (2010).
122. Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J. Stroke Cerebrovasc. Dis. DOI: 10.1016/j. jstrokecerebrovasdis.2009.12.004 (2010) (Epub ahead of print).
123. Tousoulis D, Siasos G, Stefanadis C. Aspirin resistance: what the cardiologist needs to know? Int. J. Cardiol. 132(2), 153-156 (2009).
124. Seegmiller A, Sarode R. Laboratory evaluation of platelet function. Hematol. Oncol. Clin. North Am. 21(4), 731-742, vii (2007). (Pubitemid 47102563)